相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2011
已完成
1
33.3%
尚未招募
1
33.3%
招募中
1
33.3%
暂无批准数据
- The Sabin Vaccine Institute has initiated a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, building on ongoing trials in Kenya and Uganda. - The U.S. trial will recruit 200 volunteers across four locations to evaluate safety and immunogenicity of the cAd3-based single-dose vaccine, which showed promising results in Phase 1 studies. - With no approved vaccines currently available for Marburg virus disease and recent outbreaks in Rwanda and Tanzania, this development represents a critical step toward addressing an urgent global health threat.
- Rwanda is intensifying measures against a Rift Valley Fever (RVF) outbreak following a recent resurgence near the Tanzanian border, raising concerns about potential human transmission. - The country's response includes heightened surveillance and a vaccination campaign for livestock, with 8,410 of 32,999 earmarked livestock vaccinated as of September 30, 2024. - A key challenge is the absence of rapid diagnostic tests, which hampers early detection and timely treatment, with PCR testing taking up to six hours for results. - A Phase II clinical trial of the ChAdOx1 RVF vaccine candidate has begun in Kenya, offering hope for protecting vulnerable populations against the disease.
